Continuous glucose monitoring devices could overstate blood sugar levels, with a study revealing inconsistencies in readings ...

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

Wearable health technology enhances preventive care, enabling continuous monitoring of vital signs and proactive disease management for better health outcomes.

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

Biosensors market in 2025 is driven by advanced healthcare applications, dominated by oxidoreductase enzymes and non-wearable ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...